tradmap

JANX Earnings Janux Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$2 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $5M $11M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$114M -$57M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $5M $10M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$34M -$17M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.742026-08-0610-Q
Q1 20262026-03-31-0.392026-05-0710-Q
FY 20252025-12-31-1.832026-02-2610-K
Q3 20252025-09-30-1.322025-11-0610-Q
Q2 20262025-06-30-0.932026-08-0610-Q
Q1 20262025-03-31-0.382026-05-0710-Q
FY 20252024-12-31-1.282026-02-2610-K
Q3 20252024-09-30-0.932025-11-0610-Q
Q2 20252024-06-30-0.402025-08-0710-Q
Q1 20252024-03-31-0.302025-05-0810-Q
FY 20252023-12-31-1.322026-02-2610-K
Q3 20242023-09-30-1.082024-11-0610-Q
Q2 20242023-06-30-0.842024-08-0710-Q
Q1 20242023-03-31-0.422024-05-0810-Q
FY 20242022-12-31-1.522025-02-2710-K
Q3 20232022-09-30-1.132023-11-0710-Q
Q2 20232022-06-30-0.732023-08-0810-Q
Q1 20232022-03-31-0.322023-05-0910-Q
FY 20222021-12-31-1.392023-03-1010-K
Q3 20222021-09-30-1.102022-11-1010-Q
Q2 20222021-06-30-1.522022-08-0910-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.